|
| 35789859 | Y RNAs are conserved endogenous RIG-I ligands across RNA virus infection and are targeted by HIV-1. | iScience | 2022 |
| 31175822 | Once-Weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques From Intrarectal Challenge With SHIV109CP3. | J Infect Dis | 2020 |
| 31714261 | Introduction: long-acting antiretrovirals for the treatment and prevention of HIV-1 infection: the future is now. | | 2020 |
| 31658118 | Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1. | | 2020 |
| 32759323 | Drug Resistance Mutation Frequency of Single-Genome Amplification-Derived HIV-1 Polymerase Genomes in the Cerebrospinal Fluid and Plasma of HIV-1-Infected Individuals under Nonsuppressive Therapy. | Journal of Virology | 2020 |
| 31024557 | Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial. | Front Immunol | 2019 |
| 29971734 | Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China. | AIDS and Behavior | 2019 |
| 29632541 | 5' Rapid Amplification of cDNA Ends and Illumina MiSeq Reveals B Cell Receptor Features in Healthy Adults, Adults With Chronic HIV-1 Infection, Cord Blood, and Humanized Mice. | Frontiers in Immunology | 2018 |
| 28744666 | Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial Participants. | AIDS Behav | 2018 |
| 30445896 | Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. | HIV Clin Trials | 2018 |
| 29697468 | 4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor. | | 2018 |
| 29290075 | Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States. | AIDS Behav | 2018 |
| 29633869 | Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1. | Expert Opinion on Investigational Drugs | 2018 |
| 27902508 | Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. | AIDS | 2017 |
| 28546090 | Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. | Lancet HIV | 2017 |
| 29076941 | Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis. | Journal of acquired immune deficiency syndromes (1999) | 2017 |
| 27984557 | Brief Report: The Relationship Between Injection Drug Use Risk Behaviors and Markers of Immune Activation. | Journal of acquired immune deficiency syndromes (1999) | 2017 |
| 27509238 | Challenges in Recruiting People Who Use Drugs for HIV-Related Biomedical Research: Perspectives from the Field. | AIDS Patient Care STDS | 2016 |
| 26842476 | Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques. | Journal of Virology | 2016 |
| 26684817 | Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection. | AIDS | 2016 |
| 27521361 | Chronic Hepatitis C Virus Infection and the Proinflammatory Effects of Injection Drug Use. | J Infect Dis | 2016 |
| 26049944 | Extending access with long-acting antiretroviral therapy: the next advance in HIV-1 therapeutics and prevention. | | 2015 |
| 25589630 | A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. | Science Translational Medicine | 2015 |
| 25700204 | Monoclonal antibodies to host cellular receptors for the treatment and prevention of HIV-1 infection. | | 2015 |
| 25622054 | Viral envelope is a major determinant of enhanced fitness of a multidrug-resistant HIV-1 variant. | Journal of acquired immune deficiency syndromes (1999) | 2015 |
| 25469523 | GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1. | Journal of acquired immune deficiency syndromes (1999) | 2015 |
| 26925299 | Behavioural, Mucosal and Systemic Immune Parameters in HIV-infected and Uninfected Injection Drug Users. | J Addict Res Ther | 2015 |
| 26559841 | Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic. | J Virol | 2015 |
| 24594934 | Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. | Science | 2014 |
| 25502768 | High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. | PLoS ONE | 2014 |
| 24457632 | A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. | J Acquir Immune Defic Syndr | 2014 |
| 24908550 | Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r | Lancet Infectious Diseases, The | 2014 |
| 25212686 | Early immune adaptation in HIV-1 revealed by population-level approaches. | Retrovirology | 2014 |
| 25211081 | Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. | Cell Host Microbe | 2014 |
| 24762668 | Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic. | PLoS Genet | 2014 |
| 25125210 | Single genome analysis reveals genetic characteristics of Neuroadaptation across HIV-1 envelope. | Retrovirology | 2014 |
| 24965469 | Impaired Nef function is associated with early control of HIV-1 viremia. | J Virol | 2014 |
| 24508897 | Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. | Journal of Antimicrobial Chemotherapy | 2014 |
| 23413196 | Next-generation integrase inhibitors : where to after raltegravir? | Drugs | 2013 |
| 23807155 | Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. | Journal of acquired immune deficiency syndromes (1999) | 2013 |
| 23305688 | Participation in research involving novel sampling and study designs to identify acute HIV-1 infection among minority men who have sex with men. | AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV | 2013 |
| 23664333 | Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. | Lancet Infect Dis | 2013 |
| 22180621 | The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. | J Infect Dis | 2012 |
| 22592583 | Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City. | J Acquir Immune Defic Syndr | 2012 |
| 22743596 | Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004). | Journal of acquired immune deficiency syndromes (1999) | 2012 |
| 22496233 | Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity. | J Virol | 2012 |
| 22415472 | Should we treat acute HIV infection? | Current HIV/AIDS Reports | 2012 |
| 22319447 | Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. | PLoS Pathogens | 2012 |
| 22814509 | Towards an HIV cure: a global scientific strategy. | Nat Rev Immunol | 2012 |
| 21980282 | Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. | PLoS Pathog | 2011 |